July 2015 By Mike Frick Call it a paradigm shift, a pivot, or a turn – tuberculosis (TB) vaccine research and development (R&D) is entering a period of basic science. After years of focusing on phase II clinical trials, some…
July 2015 By Mark Harrington That things just go on like this is the catastrophe. —Walter Benjamin1 Introduction Because of the lack of effective, accessible point-of-care (POC) tests for all forms of tuberculosis (TB), 1.5 million people die of this…
July 2015 By Lindsay McKenna Introduction Years of building advocacy and research capacity have finally brought about clinical research for children with tuberculosis (TB). While data gaps and delays between adult and pediatric approvals remain large, there is more activity…
July 2015 By Erica Lessem For decades, those living with tuberculosis (TB) and their providers have operated in conditions of scarcity and neglect: inadequate funding for programs and research, aging infrastructure and outdated technologies, limited scientific understanding, knowledge gaps on…
July 15, 2016 By Lindsay McKenna INTRODUCTION The roster of enrolling and planned pediatric tuberculosis (TB) treatment studies is growing. Emerging results from pharmacokinetics (PK) and safety studies continue to inform optimal dosing strategies in children and to highlight areas…
July 15, 2016 By Erica Lessem In the past year, the development of new tuberculosis (TB) drug candidates experienced some setbacks as well as some wise pruning, with the unexpected suspension of enrollment in STAND (a phase III combination trial…
July 15, 2016 By Mike Frick After decades of receiving short shrift from most national TB programs and international organizations, tuberculosis (TB) prevention is finally coming into the mainstream. In 2015, the World Health Organization (WHO) published its first-ever Guidelines…
July 15, 2016 By Erica Lessem INTRODUCTION Over the past decade, several new options for improving TB diagnosis have become available. The past year saw considerably more progress than the previous one. However, the reality of how most TB is…
February 2013 Update On Feburary 4, 2013, results from the phase IIb trial of the MVA85A vaccine in infants in South Africa (given as a booster following BCG immunization) were published in the Lancet. The vaccine proved safe but, disappointingly,…
Updates to this chapter can be found in the postscript at the end of this page. Original Report July 2012 By Erica Lessem Introduction Tuberculosis (TB) persists as a global health problem, suffering from both insufficient funding and political will…